上海复星医药(集团)股份有限公司关于控股子公司许可协议的进展公告

动脉网
Feb 25

上海复星医药公告其控股子公司许可协议进展:2014-2024年,复宏汉霖先后与KGbio、Abbott签订许可协议,授予斯鲁利单抗注射液在东南亚、中东、北非、拉丁美洲等地区的独家商业化许可。2026年2月24日,复宏汉霖与KGbio签订协议,终止《2023年独家许可协议》及KGbio终止区域独家商业化许可;同日,与Abbott签订修正案,扩展许可区域并增加里程碑付款,此次进展无需提请董事会及股东会...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10